论文部分内容阅读
Patients with stage Ⅲ N2 non-small cell lung cancer (NSCLC) are more than one third of all NSCLC patients.The 5-year survival rate of them is approximately 15%. From therapeutic views, stage ⅢA N2 of 97 International Lung Cancer Staging System is an obvious hereto-combi-nation, which includes mediastinal lymph node metasta-sis based on microscope after postoperative examination and N2 of single station or N2 of multiple stations based on computerized tomographic scanning and N2 of medi-astinallymph node mixed together.